PMAM
XERS icon

Picton Mahoney Asset Management’s Xeris Biopharma Holdings XERS Stock Holding History

Picton Mahoney Asset Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,015
Closed -$3K – 939
2024
Q3 		$3K Buy
+1,015
New +$2.61K ﹤0.01% 563

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Picton Mahoney Asset Management's XERS Position: Q4 2024 in Review

Picton Mahoney Asset Management sold out of Xeris Biopharma Holdings (XERS) in Q4 2024, closing a stake of 1,015 shares — an estimated $3K sold.

Picton Mahoney Asset Management first reported a position in XERS in Q3 2024 and held it in 1 quarter. The position peaked at $3K in Q3 2024. 162 funds tracked by Wall St. Rank hold XERS as of Q4 2024.

  • Picton Mahoney Asset Management reported no remaining Xeris Biopharma Holdings position as of Q4 2024 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 1,015 Xeris Biopharma Holdings shares in Q4 2024, an estimated $3K.
  • Picton Mahoney Asset Management first reported a position in Xeris Biopharma Holdings in Q3 2024 and held it in 1 quarter.
  • Picton Mahoney Asset Management's Xeris Biopharma Holdings position peaked at $3K in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2024.

Based on Picton Mahoney Asset Management's 13F filing for Q4 2024, filed 10 Feb 2025.